参考文献: Samir H. Barghout, et al., Treatment patterns and outcomes in KRASG12C ‐positive advanced NSCLC pa‐ tients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study, Lung Cancer, 2024....
参考文献: Samir H. Barghout, et al., Treatment patterns and outcomes in KRASG12C ‐positive advanced NSCLC pa‐ tients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study, Lung Cancer, 2024....
参考文献: Samir H. Barghout, et al., Treatment patterns and outcomes in KRASG12C ‐positive advanced NSCLC pa‐ tients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study, Lung Cancer, 2024....
Haratani K, Hayashi H, Tanaka T, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. ...
Samir H. Barghout, et al., Treatment patterns and outcomes in KRASG12C ‐positive advanced NSCLC pa‐ tients previously treated with immunecheckpointinhibitors: A Canada-wide real-world, multi-center, retrospective cohort study, Lung Cancer, 2024....
该研究通过整合性分析68例参与KRYSTAL-1临床试验的KRASG12C突变非小细胞肺癌患者在Adagrasib治疗前的转录组数据及患者进行Adagrasib治疗持续时间 (treatment duration)、无进展生存期和总生存期数据，发现富集鳞癌相关特征的患者往往具有更短的治疗持续时间，而这一现象只存在于LKB1突变的非小细胞肺癌患者亚群中。研究...
Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (≥ 50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM)[J]. Journal of Thoracic Oncology, 2023....
To date, there is no effective targeted therapy available for KRAS mutant NSCLC and targeting KRAS remains experimental. The combination of chemotherapy and MEK inhibitors has shown interesting preliminary results in KRAS mutant NSCLC and is being evaluated in phase III trials. Other drugs also are ...
Topline Data for Phase 1/2 Clinical Trial of AURN001, an Allogeneic Cell Therapy Product Candidate for the Treatment of Corneal Edema Secondary to Corneal Endothelial Dysfunction. Retrieved December 19, 2024, from https://aurionbiotech.com/aurion-biotech-announces-positive-data-for-phase_1-2_...
Haratani K, Hayashi H, Tanaka T, et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol, 2017, 28(7): 1532-1539. doi: 10.1093/annonc/mdx183 ...